TWI603971B - Novel quinoline substituted compounds - Google Patents
Novel quinoline substituted compounds Download PDFInfo
- Publication number
- TWI603971B TWI603971B TW103129036A TW103129036A TWI603971B TW I603971 B TWI603971 B TW I603971B TW 103129036 A TW103129036 A TW 103129036A TW 103129036 A TW103129036 A TW 103129036A TW I603971 B TWI603971 B TW I603971B
- Authority
- TW
- Taiwan
- Prior art keywords
- amino
- quinolin
- formula
- compound
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013172746 | 2013-08-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201542547A TW201542547A (zh) | 2015-11-16 |
| TWI603971B true TWI603971B (zh) | 2017-11-01 |
Family
ID=52483707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103129036A TWI603971B (zh) | 2013-08-22 | 2014-08-22 | Novel quinoline substituted compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9650386B2 (hu) |
| EP (1) | EP3037424B1 (hu) |
| JP (1) | JP6161705B2 (hu) |
| KR (1) | KR101906688B1 (hu) |
| CN (1) | CN105683195B (hu) |
| AU (1) | AU2014309788B2 (hu) |
| BR (1) | BR112016003247B1 (hu) |
| CA (1) | CA2922077C (hu) |
| DK (1) | DK3037424T3 (hu) |
| ES (1) | ES2656712T3 (hu) |
| HK (1) | HK1222393A1 (hu) |
| HU (1) | HUE034807T2 (hu) |
| MX (1) | MX370808B (hu) |
| MY (1) | MY182891A (hu) |
| NO (1) | NO3037424T3 (hu) |
| PH (1) | PH12016500225A1 (hu) |
| PL (1) | PL3037424T3 (hu) |
| PT (1) | PT3037424T (hu) |
| RU (1) | RU2689158C2 (hu) |
| SG (1) | SG11201600759XA (hu) |
| TW (1) | TWI603971B (hu) |
| WO (1) | WO2015025936A1 (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE034807T2 (hu) * | 2013-08-22 | 2018-02-28 | Taiho Pharmaceutical Co Ltd | Új kinolin-szubsztituált vegyület |
| JOP20190073A1 (ar) * | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| AU2017363199B2 (en) * | 2016-11-17 | 2023-08-17 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| FR3068971B1 (fr) * | 2017-07-12 | 2019-08-30 | Protneteomix | Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer |
| JOP20200044A1 (ar) | 2017-09-01 | 2020-02-26 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 |
| SG11202106986VA (en) * | 2018-12-28 | 2021-07-29 | Taiho Pharmaceutical Co Ltd | L718 and/or l792 mutant treatment-resistant egfr inhibitor |
| SG11202110376XA (en) | 2019-03-19 | 2021-10-28 | Voronoi Inc | Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component |
| CN115181104A (zh) * | 2019-09-29 | 2022-10-14 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| WO2022265950A1 (en) | 2021-06-15 | 2022-12-22 | Genentech, Inc. | Egfr inhibitor and perk activator in combination therapy and their use for treating cancer |
| CN115707704A (zh) * | 2021-08-20 | 2023-02-21 | 中山医诺维申新药研发有限公司 | 氘代稠合三环类化合物及其组合物和用途 |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| AU2006227447A1 (en) * | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-RAF kinase |
| WO2011004610A1 (ja) | 2009-07-10 | 2011-01-13 | 大鵬薬品工業株式会社 | アザ二環式化合物又はその塩 |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| MX2013007938A (es) | 2011-01-07 | 2013-11-01 | Taiho Pharmaceutical Co Ltd | Compuesto biciclico novedoso o sal del mismo. |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| ES2580530T3 (es) | 2012-02-23 | 2016-08-24 | Taiho Pharmaceutical Co., Ltd. | Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo |
| KR20150119401A (ko) * | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
| HUE034807T2 (hu) * | 2013-08-22 | 2018-02-28 | Taiho Pharmaceutical Co Ltd | Új kinolin-szubsztituált vegyület |
-
2014
- 2014-08-22 HU HUE14837210A patent/HUE034807T2/hu unknown
- 2014-08-22 CA CA2922077A patent/CA2922077C/en active Active
- 2014-08-22 JP JP2015532903A patent/JP6161705B2/ja active Active
- 2014-08-22 ES ES14837210.5T patent/ES2656712T3/es active Active
- 2014-08-22 RU RU2016110096A patent/RU2689158C2/ru active
- 2014-08-22 DK DK14837210.5T patent/DK3037424T3/en active
- 2014-08-22 SG SG11201600759XA patent/SG11201600759XA/en unknown
- 2014-08-22 PT PT148372105T patent/PT3037424T/pt unknown
- 2014-08-22 EP EP14837210.5A patent/EP3037424B1/en active Active
- 2014-08-22 KR KR1020167007071A patent/KR101906688B1/ko active IP Right Grant
- 2014-08-22 CN CN201480058192.XA patent/CN105683195B/zh active Active
- 2014-08-22 PL PL14837210T patent/PL3037424T3/pl unknown
- 2014-08-22 MY MYPI2016700465A patent/MY182891A/en unknown
- 2014-08-22 MX MX2016002125A patent/MX370808B/es active IP Right Grant
- 2014-08-22 BR BR112016003247-0A patent/BR112016003247B1/pt active IP Right Grant
- 2014-08-22 TW TW103129036A patent/TWI603971B/zh active
- 2014-08-22 US US14/911,093 patent/US9650386B2/en active Active
- 2014-08-22 AU AU2014309788A patent/AU2014309788B2/en active Active
- 2014-08-22 NO NO14837210A patent/NO3037424T3/no unknown
- 2014-08-22 WO PCT/JP2014/071951 patent/WO2015025936A1/ja active Application Filing
-
2016
- 2016-02-02 PH PH12016500225A patent/PH12016500225A1/en unknown
- 2016-09-06 HK HK16110581.6A patent/HK1222393A1/zh unknown
- 2016-12-19 US US15/382,883 patent/US9758526B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI603971B (zh) | Novel quinoline substituted compounds | |
| TWI496783B (zh) | Quinolylpyrrolopyrimidine condensed cyclic compounds or salts thereof | |
| JP6035423B2 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
| TW201619150A (zh) | 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物 | |
| TW201336847A (zh) | 喹啉基吡咯并嘧啶化合物或其鹽 | |
| JP2018511634A (ja) | Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
| RU2797117C2 (ru) | Новое хинолин-замещенное соединение |